Letter of Intent Template for Acquiring a Clinical Laboratory or Diagnostics Company

Buyer and Seller Identification

Clearly identify the acquiring entity and the target business, including its legal name, CLIA certification number, and primary operating location. In lab acquisitions, it matters whether the buyer is acquiring the legal entity (stock purchase) or the assets of the business, as this directly affects how CLIA certification, state laboratory licenses, and Medicare/Medicaid provider numbers are transferred or reapplied for.

💡 Sellers often prefer stock purchases to avoid triggering Medicare and Medicaid change-of-ownership (CHOW) re-enrollment processes, which can create a gap in billing privileges. Buyers frequently prefer asset purchases to avoid assuming historical billing compliance liabilities. Negotiate this structure early — it affects regulatory timelines, indemnification exposure, and how payer contracts are assigned. If an asset purchase is chosen, confirm whether the Seller's CLIA certificate can be transferred or whether a new application is required in your state.

Purchase Price and Valuation Basis

State the proposed purchase price, the valuation methodology used (typically a multiple of trailing twelve-month EBITDA or seller's discretionary earnings), and any assumptions baked into the offer. Lab acquisitions in the lower middle market typically transact at 3.5x–6.5x EBITDA, with higher multiples reserved for labs with specialty assays, CAP accreditation, diversified payer mixes, and low customer concentration.

💡 Sellers in the lab space frequently present adjusted EBITDA figures that add back the cost of a replacement lab director or medical director, arguing these costs are below-market. Push back carefully — a qualified lab director is both a regulatory necessity and an operational cost you will incur. Also scrutinize whether PAMA-driven reimbursement cuts have already compressed margins in the trailing period or whether the next rate schedule will materially reduce forward earnings. Build downward price adjustment triggers into the LOI tied to these variables.

Deal Structure and Consideration

Define how the purchase price will be paid — cash at close, seller financing, earnout, or a combination. Lab acquisitions frequently include seller financing or earnout provisions to account for the risk that payer contracts may not be successfully assigned, key referring physicians may reduce volume, or regulatory re-enrollment creates a temporary billing gap post-close.

💡 Earnout structures are common in lab deals precisely because referring physician loyalty and payer contract continuity are the two largest post-close variables. Be specific about how volume is measured — gross specimen volume, net collected revenue, or billed charges are very different metrics. Sellers will push for the broadest possible earnout triggers; buyers should insist on net collected revenue from named accounts to avoid disputes. Seller financing signals the seller's confidence in the business and reduces SBA loan sizing, which can improve deal economics.

Due Diligence Period and Access

Define the length of the due diligence period, the categories of information the buyer will require access to, and any limitations on physical access to the lab during the process. Lab due diligence is multi-dimensional — financial, regulatory, clinical, and operational — and typically requires more time than standard service business deals.

💡 Sixty days is a realistic minimum for a lab deal — regulatory review alone can take two to three weeks if you engage outside healthcare compliance counsel. If the seller is resistant to sharing payer contract details or CMS audit history early in due diligence, treat this as a significant red flag. Also request the lab's denial rate and days sales outstanding (DSO) trend — labs with billing problems often have DSO exceeding 90 days and denial rates above 15%, both of which suppress true cash collections relative to what the income statement suggests.

Regulatory and Licensing Contingencies

Explicitly condition the transaction on the successful transfer, assignment, or re-issuance of all material regulatory approvals required for the buyer to legally operate the laboratory. This is one of the most critical and lab-specific sections of the LOI, as operating a clinical laboratory without proper CLIA certification or Medicare enrollment is both a legal violation and a billing catastrophe.

💡 CHOW re-enrollment under Medicare can take 60–120 days and creates a real risk of billing gaps if not planned carefully. Work with a healthcare regulatory attorney to determine whether a 'change of ownership' under 42 CFR Part 493 triggers automatic CLIA certificate reissuance in your state. Some deals use a management services agreement (MSA) during the transition period to allow the seller's entity to continue billing while the buyer completes enrollment. Sellers will resist accepting the full risk of delayed enrollment — negotiate a shared cost structure for the transition period.

Payer Contract Assignment and Revenue Continuity

Address how existing commercial payer contracts, Medicare/Medicaid provider agreements, and hospital or physician group master service agreements will be handled at closing. Payer contract assignment is often the single largest source of post-close revenue risk in a lab acquisition.

💡 Many commercial lab contracts include anti-assignment clauses or require the payer's written consent for a change of ownership. Some payers use CHOW events as an opportunity to renegotiate rates downward or terminate the contract entirely, particularly if the buyer is a PE-backed roll-up the payer has existing network conflicts with. Request a full contract-by-contract review during due diligence — including termination-for-convenience clauses, rate renegotiation triggers, and exclusivity provisions. Sellers will resist price adjustment mechanisms tied to payer contract loss; buyers should insist on escrow holdbacks sized to cover at least 12 months of revenue from the most concentrated payer relationships.

Exclusivity and No-Shop Provision

Establish a period during which the seller agrees not to solicit, entertain, or advance discussions with other potential buyers while the buyer completes due diligence and works toward a definitive agreement.

💡 Sixty days of exclusivity is standard for lower middle market lab deals; sellers who have engaged a healthcare M&A broker may push back for 45 days. Resist anything shorter given the regulatory complexity involved — CLIA review, payer contract analysis, and equipment appraisal alone can consume the first 30 days. If the seller is reluctant to grant exclusivity at all, this signals they are either running a competitive process or not fully committed to a transaction, both of which should inform your pricing and risk assumptions.

Confidentiality and Non-Disclosure

Confirm that the parties are bound by a mutual non-disclosure agreement covering all information exchanged during due diligence, and address the handling of sensitive patient data, proprietary test methodologies, and referring physician relationship details.

💡 HIPAA compliance is not optional in lab due diligence — patient data cannot be shared with a buyer without appropriate safeguards, and any breach during the process creates liability for both parties. Structure data room access so that de-identified financial and operational data is reviewed first, with any identifiable patient records reviewed only by licensed healthcare professionals under a formal data use agreement if required at all. Sellers should also protect their referring physician lists carefully — this is their most valuable proprietary asset and can be weaponized by a buyer who ultimately walks away from the deal.

Employee and Lab Director Retention

Address the buyer's intentions regarding existing employees, including the lab director, medical director, certified laboratory scientists, and administrative billing staff, all of whom are operationally and regulatorily critical to an uninterrupted lab transition.

💡 The lab director is not merely a key employee — they are a regulatory necessity. Under CLIA regulations, every certified laboratory must have a qualified lab director whose credentials match the complexity level of testing performed. If the current lab director plans to leave post-acquisition, the buyer must identify a credentialed replacement before closing, not after. Build a lab director retention bonus (funded from escrow) into the definitive agreement and negotiate a minimum 90-day post-close transition period as a non-negotiable closing condition. Sellers should disclose any existing verbal commitments about retirement or departure made to current clinical staff.

Representations and Warranties Preview

Signal the key representations and warranties the buyer will require in the definitive purchase agreement, allowing the seller to begin preparing and identifying any exceptions that will need to be disclosed in the schedules.

💡 Lab-specific reps and warranties around billing compliance and regulatory history are non-negotiable for any sophisticated buyer. Sellers who push back on billing compliance representations or seek to carve out all pre-closing audit risk should be viewed with significant caution. A well-run, compliant lab has nothing to hide. Indemnification tied to these reps should survive closing for a minimum of three years given the statute of limitations on Medicare false claims act exposure. Consider requiring a representation and warranty insurance (RWI) policy for transactions above $3M to reduce friction on indemnification caps.

Closing Conditions and Timeline

Outline the expected timeline from LOI execution to closing and the key milestones and conditions that must be satisfied before the transaction can close.

💡 Lab deals routinely take longer than expected due to regulatory timelines outside either party's control. Build buffer into your closing timeline and avoid making commitments to your lender or investors based on optimistic closing dates. The Medicare CHOW process alone can take 60–90 days from submission of the CMS-855B form, and state laboratory license reissuance timelines vary significantly by jurisdiction. Sellers who are motivated to close quickly sometimes underestimate regulatory timelines — set realistic expectations in the LOI to avoid frustration and avoid giving either party grounds to claim the other is dragging their feet.